Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands.
Clin Pharmacol Ther. 2012 Apr;91(4):718-25. doi: 10.1038/clpt.2011.297. Epub 2012 Mar 7.
In this investigation we evaluate the relevance of a model-based approach for pharmacokinetic (PK) bridging and dose selection of drug combinations in children. The fixed-dose combination of atovaquone (ATV) and proguanil (PGN) was used for illustration purposes. A population PK model was developed for each compound using plasma concentration data from adult and pediatric patients. PK parameter estimates were subsequently used to simulate drug exposure in children treated with different dose levels of these drugs. We show that, contrary to common practice, different dose ratios may be required across age groups in order to achieve target exposure levels comparable to adults. This example illustrates the effects of covariate interactions, specifically the ones involving body weight (BW) and ethnicity, on the PK of drugs. A model-based approach is critical for dose selection and the rational use of drug combinations in children. Flexible rather than fixed-dose ratios may be needed to ensure comparable target exposure in bridging studies.
在本研究中,我们评估了基于模型的方法在儿童药物组合药代动力学(PK)桥接和剂量选择中的相关性。阿托伐醌(ATV)和丙氧喹(PGN)固定剂量组合用于说明目的。使用来自成人和儿科患者的血浆浓度数据,为每种化合物开发了群体 PK 模型。随后,使用 PK 参数估计值模拟了接受这些药物不同剂量水平治疗的儿童的药物暴露情况。我们表明,与常见做法相反,为了达到与成人相当的目标暴露水平,可能需要在不同年龄组之间使用不同的剂量比。该示例说明了协变量相互作用(特别是涉及体重(BW)和种族的相互作用)对药物 PK 的影响。基于模型的方法对于儿童的剂量选择和药物组合的合理使用至关重要。在桥接研究中,为了确保可比的目标暴露,可能需要灵活的剂量比,而不是固定的剂量比。